SOMATULINE PR 30mg powder + solvent for suspension injection with prolonged release medication leaflet

H01CB03 lanreotide • Systemic hormonal preparations, excluding sex hormones and insulins | Hypothalamic hormones | Somatostatin and analogues

Lanreotide is a somatostatin analog used to treat acromegaly and certain neuroendocrine tumors. It works by inhibiting the secretion of hormones such as growth hormone and reducing blood flow to neuroendocrine tumors.

The medication is administered as subcutaneous injections, usually once every 4 weeks, as directed by a doctor. The treatment is effective in controlling symptoms and slowing disease progression.

Side effects may include pain at the injection site, nausea, diarrhea, or fatigue. In rare cases, severe allergic reactions or gallstone formation may occur.

Patients should strictly follow their doctor's instructions and inform them about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.

General data about SOMATULINE PR 30mg

Substance: lanreotide

Date of last drug list: 01-12-2022

Commercial code: W58561001

Concentration: 30mg

Pharmaceutical form: powder + solvent for suspension injection with prolonged release

Quantity: 1

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: IPSEN PHARMA BIOTECH - FRANTA

Holder: IPSEN PHARMA - FRANTA

Number: 10662/2018/01

Shelf life: 2 years

Concentrations available for lanreotide

120mg, 30mg, 60mg, 90mg

Other substances similar to lanreotide